<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627065</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-207</org_study_id>
    <secondary_id>Parsaclisib</secondary_id>
    <nct_id>NCT03627065</nct_id>
  </id_info>
  <brief_title>A Study of INCB050465 in Primary Sjögren's Syndrome</brief_title>
  <official_title>An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of
      Sjögren's syndrome (SS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">January 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with a 1 point or greater change on the salivary gland ultrasound (SGUS) score for parotid and submandibular glands</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>To determine the impact of parsaclisib on salivary gland echostructure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in salivary CXCL13 levels</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>To assess the impact of parsaclisib on salivary CXCL13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>Parsaclisib administered orally once daily at the protocol-defined dose.</description>
    <arm_group_label>Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary SS diagnosed according to the revised American-European Consensus Group (AECG)
             criteria.

          -  Minimum score of 2 on the SGUS score for parotid and submandibular glands.

          -  EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ≥ 5.

          -  Positive serum titers of anti-SS-A and/or anti-SS-B antibodies.

          -  Symptomatic oral dryness score of at least 5 on patient questionnaire.

          -  Willingness to avoid pregnancy or fathering children based on protocol-defined
             criteria.

        Exclusion Criteria:

          -  Diagnosis of secondary SS according to the revised AECG criteria (eg, the presence of
             a previously diagnosed or a present diagnosis of rheumatoid arthritis, systemic lupus
             erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis,
             dermatomyositis, immunoglobulin G4-related disorder, sarcoidosis, or any other defined
             autoimmune rheumatologic disorder).

          -  Concurrent conditions and history of other diseases per protocol-defined criteria.

          -  Positive test results for tuberculosis (TB) from the QuantiFERON-TB Gold test or
             T-spot.TB test.

          -  Positive serology test results for HIV antibody, hepatitis B surface antigen,
             hepatitis B surface antigen antibody, HBV core antibody, or HCV (HCV antibody with
             positive HCV-RNA).

          -  Severely impaired liver function (Child-Pugh Class C).

          -  Prior or ongoing therapy with protocol-defined drugs.

          -  Receipt of any live vaccine in the 30 days before screening.

          -  No major surgery within 30 days before screening. Inadequate recovery from toxicity
             and/or complications from a major surgery before starting therapy.

          -  Current alcohol or drug use that, in the opinion of the investigator, will interfere
             with the participant's ability to comply with the dose regimen and study evaluations.

          -  Laboratory values at screening outside the protocol-defined ranges.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Pharma CR</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology Group</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramesh C. Gupta, MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119-5208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Sjögren's syndrome</keyword>
  <keyword>PI3Kδ inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

